The extreme dilution from the zero-price exercise warrants will likely overwhelm any near-term cash infusion. Monitor for immediate selling pressure as the market prices in the potential 30x-60x increase in share count. The over-allotment option's 30-day window adds further uncertainty.
Price Chart
Executive Summary
China SXT Pharmaceuticals is conducting a dilutive offering of up to 8,000,000 units (plus an over-allotment option for up to 8,000,000 additional units) at $1.50 per unit, each consisting of one Class A ordinary share (or pre-funded warrant) and one ordinary warrant with a zero-price exercise feature. The offering is priced at a 337% premium to the last closing price of $0.3435, but the warrants' zero-price exercise mechanism will likely result in massive dilution — up to 72,000,000 additional shares (or 144,000,000 with the over-allotment) without any cash proceeds to the company. Existing shareholders face an immediate dilution of $17.27 per share, while new investors see 57% dilution at the offering price.
Key Facts
- Offering of up to 8,000,000 units at $1.50/unit, each consisting of one Class A ordinary share (or pre-funded warrant) and one ordinary warrant with a zero-price exercise feature
- Last reported sale price on October 8, 2026 was $0.3435 per share — offering priced at a 337% premium
- Ordinary warrants have a $2.75 exercise price but a zero-price exercise feature that allows holders to receive shares without paying cash when the stock's VWAP is below $2.75
- Assuming full exercise of warrants at the $0.50 floor price, up to 72,000,000 additional shares could be issued with zero cash proceeds to the company
- Over-allotment option allows investors to acquire up to $12,000,000 of additional securities on same terms within 30 days
- Pro forma as-adjusted net tangible book value drops from $17.92/share to $0.65/share — existing shareholders face $17.27/share dilution
- New investors experience immediate dilution of $0.85/share, or 57% of the offering price
- Net proceeds to the company estimated at approximately $11.06 million for working capital and general corporate purposes
- No minimum offering requirement — the offering can close regardless of how many units are sold
- Company had 2,357,498 Class A ordinary shares outstanding prior to the offering; post-offering could reach 82,357,498 (or 162,357,498 with over-allotment)
Financial Impact
Up to $12,000,000 gross proceeds from unit sales, but warrants will likely be exercised via zero-price mechanism yielding zero additional cash. Massive dilution: existing shareholders see net tangible book value per share drop from $17.92 to $0.65.
Risk Factors
- Massive dilution: share count could increase from 2.4M to 82M+ (or 162M+ with over-allotment), destroying existing shareholder value
- Zero-price exercise feature means warrants provide no future cash to the company while still diluting shareholders
- Stock trading at $0.3435 — well below the $1.00 Nasdaq minimum bid price requirement, adding delisting risk
- No minimum offering requirement — the offering can close with partial subscription, leaving the company with less cash than anticipated
- Company has a history of repeated dilutive financings (April, May, July 2026) suggesting ongoing capital needs
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-108254 |
| Document: 0001213900-26-108254-index-headers.html | 0001213900-26-108254 |
| Document: 0001213900-26-108254-index.html | 0001213900-26-108254 |
| Document: 0001213900-26-108254.txt | 0001213900-26-108254 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.0480 | awaiting T+5 | — | — |
Oct 15, 2026 11d ago | SC 13G | $0.0650 $0.0410 | ▼ −36.92% | ▼ −36.49% | — |
Oct 9, 2026 17d ago | 6-K | $0.1020 $0.1112 | ▼ −9.02% | ▼ −10.51% | — |
Oct 9, 2026 17d ago | 424B5 | $0.1487 $0.0650 | ▲ +56.29% | ▲ +54.32% | — |
Oct 8, 2026 18d ago | 6-K | $0.3435 $0.0688 | ▲ +79.97% | ▲ +79.69% | — |
Oct 8, 2026 18d ago | 6-K | $0.3435 $0.0688 | ▲ +79.97% | ▲ +79.69% | — |
Sep 17, 2026 5w ago | EFFECT | $2.44 $2.55 | ▼ −4.72% | ▼ −4.12% | — |
Aug 28, 2026 8w ago | 6-K | $2.56 $2.24 | ▲ +12.50% | ▲ +12.36% | — |
Jul 24, 2026 13w ago | 424B5 | $0.0638 $0.0618 | ▲ +3.13% | ▲ +4.23% | — |
Jun 1, 2026 21w ago | 424B5 | $1.78 $1.56 | ▲ +12.36% | ▲ +9.39% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers